Clinical Trials
Select Clinical Trials of RAS(ON) Inhibitors
At Revolution Medicines, we are committed to the discovery, development, and delivery of targeted therapies for patients with RAS-mutant cancer. Our RAS(ON) Inhibitor Clinical Trial Program is evaluating molecules aimed at targeting a broad range of RAS-mutant cancers. Rat sarcoma virus (RAS) is a protein that is important in regulating cell division in our bodies. In certain cancers known as RAS-mutant cancers, changes (or mutations) in the RAS gene cause the RAS protein to become mostly switched ON (or active), allowing the cancer cells to grow, spread, and survive.
Investigational RAS(ON) inhibitors currently under development include:
- Daraxonrasib (RMC-6236), an oral, RAS(ON) multi-selective inhibitor that is selective for the active or "(ON)" state of multiple mutant forms of RAS (G12X, G13X, Q61X)
- Zoldonrasib (RMC-9805), an oral, RAS(ON) mutant-selective inhibitor that is selective for the active or "(ON)" state of RAS G12D
- Elironrasib (RMC-6291), an oral, RAS(ON) mutant-selective inhibitor that is selective for the active or "(ON)" state of RAS G12C
RAS(ON) Inhibitor Clinical Trial Program
aThis is not a complete list of eligibility criteria; for more information, please go to ClinicalTrials.gov.
To potentially enroll in one of the above Revolution Medicines clinical trials, Patients should discuss with their doctor whether they qualify for one of the above Revolution Medicines clinical trials.
These are select clinical trials only. To learn more about all our clinical trials, visit ClinicalTrials.gov. For questions on our clinical trials, please reach out to medinfo@revmed.com or 1-844-2-REVMED (1-844-273-8633).
The safety and efficacy of the agents and/or uses under investigation have not been established.
